These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 18445891)

  • 1. Contribution of inflammation to vascular disease in chronic kidney disease patients.
    Suliman ME; Stenvinkel P
    Saudi J Kidney Dis Transpl; 2008 May; 19(3):329-45. PubMed ID: 18445891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease.
    Yao Q; Pecoits-Filho R; Lindholm B; Stenvinkel P
    Scand J Urol Nephrol; 2004; 38(5):405-16. PubMed ID: 15764253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.
    Suliman ME; Lindholm B; Bárány P; Qureshi AR; Stenvinkel P
    Semin Dial; 2007; 20(6):523-9. PubMed ID: 17991198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients.
    de Mutsert R; Grootendorst DC; Axelsson J; Boeschoten EW; Krediet RT; Dekker FW;
    Nephrol Dial Transplant; 2008 Sep; 23(9):2957-64. PubMed ID: 18400817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protecting the endothelium: a new focus for management of chronic kidney disease.
    Diaz-Buxo JA; Woods HF
    Hemodial Int; 2006 Jan; 10(1):42-8. PubMed ID: 16441826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients.
    Yao Q; Lindholm B; Stenvinkel P
    Hemodial Int; 2004 Apr; 8(2):118-29. PubMed ID: 19379407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diet, inflammation, and chronic kidney disease: getting to the heart of the matter.
    Neade T; Uribarri J
    Semin Dial; 2008; 21(4):331-7. PubMed ID: 18573134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients.
    Valli A; Carrero JJ; Qureshi AR; Garibotto G; Bárány P; Axelsson J; Lindholm B; Stenvinkel P; Anderstam B; Suliman ME
    Clin Chim Acta; 2008 Sep; 395(1-2):106-10. PubMed ID: 18565329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights on inflammation in chronic kidney disease-genetic and non-genetic factors.
    Stenvinkel P
    Nephrol Ther; 2006 Jul; 2(3):111-9. PubMed ID: 16890135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should we quantify insulin resistance in patients with renal disease?
    Shen Y; Peake PW; Kelly JJ
    Nephrology (Carlton); 2005 Dec; 10(6):599-605. PubMed ID: 16354245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic kidney disease (CKD) as an independent risk factor for cardiovascular disease (CVD)].
    Minami J; Ishimitsu T; Sudo Y; Matsuoka H
    Nihon Rinsho; 2008 Sep; 66(9):1657-63. PubMed ID: 18788391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic inflammation and cardiovascular risk in hemodialysis].
    Pertosa G; Simone S; Soccio M; Marrone D; Grandaliano G
    G Ital Nefrol; 2003; 20(6):631-40. PubMed ID: 14732917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality.
    Suliman ME; Qureshi AR; Carrero JJ; Bárány P; Yilmaz MI; Snaedal-Jonsdottir S; Alvestrand A; Heimbürger O; Lindholm B; Stenvinkel P
    QJM; 2008 May; 101(5):397-405. PubMed ID: 18292098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density in end-stage renal disease patients: association with wasting, cardiovascular disease and mortality.
    Matsubara K; Suliman ME; Qureshi AR; Axelsson J; Martola L; Heimbürger O; Barany P; Stenvinkel P; Lindholm B
    Blood Purif; 2008; 26(3):284-90. PubMed ID: 18421213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease.
    Roberts MA; Hare DL; Ratnaike S; Ierino FL
    Am J Kidney Dis; 2006 Sep; 48(3):341-60. PubMed ID: 16931208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical epidemiology of cardiovascular disease in chronic kidney disease.
    Kundhal K; Lok CE
    Nephron Clin Pract; 2005; 101(2):c47-52. PubMed ID: 15942250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods.
    Imai E; Matsuo S; Makino H; Watanabe T; Akizawa T; Nitta K; Iimuro S; Ohashi Y; Hishida A;
    Hypertens Res; 2008 Jun; 31(6):1101-7. PubMed ID: 18716357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease.
    Stenvinkel P; Lindholm B; Heimbürger O
    Semin Dial; 2004; 17(6):505-15. PubMed ID: 15660582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality.
    Tong M; Carrero JJ; Qureshi AR; Anderstam B; Heimbürger O; Bárány P; Axelsson J; Alvestrand A; Stenvinkel P; Lindholm B; Suliman ME
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):889-97. PubMed ID: 17702732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic kidney disease increases cardiovascular mortality in 80-year-old subjects in Japan.
    Kagiyama S; Matsumura K; Ansai T; Soh I; Takata Y; Awano S; Sonoki K; Yoshida A; Takehara T; Iida M
    Hypertens Res; 2008 Nov; 31(11):2053-8. PubMed ID: 19098377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.